Literature DB >> 29434994

MicroRNA-122-3p inhibits tumor cell proliferation and induces apoptosis by targeting Forkhead box O in A549 cells.

Wen Wang1,2, Jinsong Yang1, Fenglei Yu2, Wenjie Li3, Li Wang2, Haoyu Zou1, Xia Long1.   

Abstract

The imbalance between cell proliferation and apoptosis was implicated to serve key roles in cancer pathogenesis. The characteristics of microRNAs (miRNAs/miRs) have attracted much attention in research focusing on cancer pathogenesis in recent years. miR-122-3p has been reported to be associated with a number of disease processes and pathogenesis, including lung cancer. The present study aimed to investigate the association of miR-122-3p expression level with cell proliferation and apoptosis in a lung cancer cell line. A549 cells were transfected with miR-122-3p to interrupt the expression of miR-122-3p. Subsequently, MTT and BrdU assay, and western blot were used to analyze the influence of miR-122-3p on lung cancer cell proliferation, cell viability and its underlying mechanism. The present study revealed that, by targeting p27, overexpression of miR-122-3p inhibited cell proliferation in lung cancer. Furthermore, the cell apoptosis analysis suggested that overexpression of miR-122-3p was able to inhibit cell apoptosis by targeting Forkhead box O. These findings suggest that miR-122-3p may be associated with the pathology and progression of lung cancer and be a new therapeutic target for this disease.

Entities:  

Keywords:  A549; Forkhead box O; lung cancer; microRNA-122-3p; p27

Year:  2017        PMID: 29434994      PMCID: PMC5777312          DOI: 10.3892/ol.2017.7577

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells.

Authors:  Jingwen Hu; Mantang Qiu; Feng Jiang; Shuai Zhang; Xin Yang; Jie Wang; Lin Xu; Rong Yin
Journal:  Tumour Biol       Date:  2014-06-06

2.  Surgical treatment of bone metastases in patients with lung cancer.

Authors:  Sandra Utzschneider; Ewa Wicherek; Patrick Weber; Gerwin Schmidt; Volkmar Jansson; Hans Roland Dürr
Journal:  Int Orthop       Date:  2010-06-18       Impact factor: 3.075

3.  PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor.

Authors:  Octavian Bucur; Andreea Lucia Stancu; Maria Sinziana Muraru; Armelle Melet; Stefana Maria Petrescu; Roya Khosravi-Far
Journal:  Discoveries (Craiova)       Date:  2014 Apr-Jun

Review 4.  Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer.

Authors:  Mina Maftouh; Amir Avan; Elena Galvani; Godefridus J Peters; Elisa Giovannetti
Journal:  Crit Rev Oncog       Date:  2013

5.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

6.  Co-expression of ILT4/HLA-G in human non-small cell lung cancer correlates with poor prognosis and ILT4-HLA-G interaction activates ERK signaling.

Authors:  Yanwen Zhang; Jianqiang Zhao; Lijun Qiu; Pei Zhang; Juan Li; Dong Yang; Xiaojuan Wei; Yali Han; Siyue Nie; Yuping Sun
Journal:  Tumour Biol       Date:  2016-03-03

7.  Overexpression of MEOX2 and TWIST1 is associated with H3K27me3 levels and determines lung cancer chemoresistance and prognosis.

Authors:  Federico Ávila-Moreno; Leonel Armas-López; Aldo M Álvarez-Moran; Zoila López-Bujanda; Blanca Ortiz-Quintero; Alfredo Hidalgo-Miranda; Francisco Urrea-Ramírez; R María Rivera-Rosales; Eugenia Vázquez-Manríquez; Erika Peña-Mirabal; José Morales-Gómez; Juan C Vázquez-Minero; José L Téllez-Becerra; Roberto Ramírez-Mendoza; Alejandro Ávalos-Bracho; Enrique Guzmán de Alba; Karla Vázquez-Santillán; Vilma Maldonado-Lagunas; Patricio Santillán-Doherty; Patricia Piña-Sánchez; Joaquin Zúñiga-Ramos
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

8.  Prognostic significance of p21, p27 and survivin protein expression in patients with oral squamous cell carcinoma.

Authors:  Mingbin Zhang; Jiang Li; Lizhen Wang; Zhen Tian; Ping Zhang; Qin Xu; Chenping Zhang; Fengcai Wei; Wantao Chen
Journal:  Oncol Lett       Date:  2013-06-07       Impact factor: 2.967

9.  Estrogen-related receptor γ is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27.

Authors:  Ji-Hyun Kim; Yeon-Kyung Choi; Jun-Kyu Byun; Mi-Kyung Kim; Yu Na Kang; Seong Heon Kim; Sungwoo Lee; Byoung Kuk Jang; Keun-Gyu Park
Journal:  Exp Mol Med       Date:  2016-03-04       Impact factor: 8.718

10.  E2F1-induced upregulation of long noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically silencing of CKIs.

Authors:  Erbao Zhang; Dandan Yin; Liang Han; Xuezhi He; Xinxin Si; Wenming Chen; Rui Xia; Tongpeng Xu; Dongying Gu; Wei De; Renhua Guo; Zhi Xu; Jinfei Chen
Journal:  Oncotarget       Date:  2016-04-26
View more
  3 in total

1.  MiRAR-miRNA Activity Reporter for Living Cells.

Authors:  Matthew A Turk; Christina Z Chung; Emad Manni; Stephanie A Zukowski; Anish Engineer; Yasaman Badakhshi; Yumin Bi; Ilka U Heinemann
Journal:  Genes (Basel)       Date:  2018-06-19       Impact factor: 4.096

2.  Extracellular small non-coding RNA contaminants in fetal bovine serum and serum-free media.

Authors:  Bettina Mannerström; Riku O Paananen; Ahmed G Abu-Shahba; Jukka Moilanen; Riitta Seppänen-Kaijansinkko; Sippy Kaur
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

3.  Downregulation of hTERT contributes to ovarian cancer apoptosis and inhibits proliferation of ovarian cancer cells.

Authors:  Qing-An-Zi Wang; Xiaolei Liang; Yongxiu Yang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.